Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells

Cancer Gene Therapy

Volumn 8, Issue 12, 2001, Pages 966-973

  Takebe, Naoko ^a   Zhao, Shi Cheng ^a   Ural, Ali U ^b   Johnson, Martin R ^c   Banerjee, Debabrata ^a   Diasio, Robert B ^c   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c University of Alabama at Birmingham   (United States)

Author keywords

CD34+ cells; DPD; Drug resistance; Fluoropyrimidine; Retroviral vector

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; KANAMYCIN KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CELL STRAIN 3T3; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESISTANCE; ENZYME ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; VIRUS INFECTION; WESTERN BLOTTING;

3T3 CELLS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DNA, COMPLEMENTARY; DRUG RESISTANCE; FLUOROURACIL; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; OXIDOREDUCTASES; RETROVIRIDAE; TRANSFECTION;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0035213225     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700393     Document Type: Article

References (36)

1. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients
2. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: A phase two study
3. Intensive therapy with cyclophosphamide, carmustine, etoposide±cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
4. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients
5. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumors
6. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity
7. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction
8. Clinical pharmacology of cancer chemotherapy in cancer - Principles and practice of oncology
9. 5-Fluoropyrimidines
10. Clinical pharmacology of 5-fluorouracil
11. Metabolism of pyrimidine analogues and their nucleosides
12. Purification and characterization of dihydropyrimidine dehydrogenase from human liver
13. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified patients, and clinical implication in 5-fluorouracil chemotherapy
14. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluoruracil as a substrate
15. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
16. Familial deficiency of dihydropyrimidine dehydrogenase
17. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome
18. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity
19. Enhancement of 5-fluorouracil chemotherapy with emphasis on the use of excess thymidine
20. Degradation of pyrimidines and pyrimidine analogs - Pathways and mutual influences
21. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy
22. Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil
23. Total marrow failure induced by pegylated stem cell factor administered before 5-fluorouracil
24. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors
25. A safe packaging line for gene transfer: Separating viral genes on two different plasmids
26. Construction and use of a safe and efficient amphotropic packaging cell line
27. Active sitedirected double mutants of dihydrofolate reductase
28. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo
29. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT
30. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO
31. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
32. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
33. +cells from Gaucher patient
34. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
35. The hematologic effects of folate analogs: Implications for using the dihydrofolate reductase gene for in vivo selection